Stock Track | Merck Soars 5.00% Intraday on Lawsuit Settlement, HIV Drug Progress in China, and Analyst Support

Stock Track06-05 03:30

Merck & Co.'s stock surged 5.00% during Thursday's intraday trading session. The significant upward movement was driven by a combination of company-specific positive developments and broader sector strength.

The pharmaceutical giant announced it will pay over $50 million to settle more than 200 lawsuits related to its Gardasil cancer vaccine. The settlement resolves claims that the vaccine caused autoimmune ailments in young women, removing a potential overhang of legal uncertainty for the company.

Concurrently, Merck received a regulatory boost in China, where health authorities proposed granting priority review status to its doravirine/islatravir tablet, a two-drug regimen for adult HIV-1 infection. This designation could accelerate the drug's path to market in a key region. Furthermore, analyst sentiment remained positive, with Goldman Sachs reaffirming its Buy rating on Merck and maintaining a $137 price target, providing additional confidence to investors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187394428?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187394428","market":"sg","top_or_hot":-1,"title":"Stock Track | Merck Soars 5.00% Intraday on Lawsuit Settlement, HIV Drug Progress in China, and Analyst Support","media":"Stock Track","content":"<p>Merck & Co.'s stock surged 5.00% during Thursday's intraday trading session. The significant upward movement was driven by a combination of company-specific positive developments and broader sector strength.</p><p>The pharmaceutical giant announced it will pay over $50 million to settle more than 200 lawsuits related to its Gardasil cancer vaccine. The settlement resolves claims that the vaccine caused autoimmune ailments in young women, removing a potential overhang of legal uncertainty for the company.</p><p>Concurrently, Merck received a regulatory boost in China, where health authorities proposed granting priority review status to its doravirine/islatravir tablet, a two-drug regimen for adult HIV-1 infection. This designation could accelerate the drug's path to market in a key region. Furthermore, analyst sentiment remained positive, with Goldman Sachs reaffirming its Buy rating on Merck and maintaining a $137 price target, providing additional confidence to investors.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Merck Soars 5.00% Intraday on Lawsuit Settlement, HIV Drug Progress in China, and Analyst Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Merck Soars 5.00% Intraday on Lawsuit Settlement, HIV Drug Progress in China, and Analyst Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-05 03:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck & Co.'s stock surged 5.00% during Thursday's intraday trading session. The significant upward movement was driven by a combination of company-specific positive developments and broader sector strength.</p><p>The pharmaceutical giant announced it will pay over $50 million to settle more than 200 lawsuits related to its Gardasil cancer vaccine. The settlement resolves claims that the vaccine caused autoimmune ailments in young women, removing a potential overhang of legal uncertainty for the company.</p><p>Concurrently, Merck received a regulatory boost in China, where health authorities proposed granting priority review status to its doravirine/islatravir tablet, a two-drug regimen for adult HIV-1 infection. This designation could accelerate the drug's path to market in a key region. Furthermore, analyst sentiment remained positive, with Goldman Sachs reaffirming its Buy rating on Merck and maintaining a $137 price target, providing additional confidence to investors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":"","article_id":"1187394428","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187394428","pubTimestamp":1780601445,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Merck & Co.'s stock surged 5.00% during Thursday's intraday trading session. The significant upward movement was driven by a combination of company-specific positive developments and broader sector...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东"},"translate_title":"个股追踪|默沙东盘中大涨5.00%因诉讼和解、HIV药物在华进展、分析师支持","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"Merck & Co.'s stock surged 5.00% during Thursday's intraday trading session. The significant upward movement was driven by a combination of company-specific positive developments and broader sector strength.The pharmaceutical giant announced it will pay over $50 million to settle more than 200 lawsuits related to its Gardasil cancer vaccine. The settlement resolves claims that the vaccine caused autoimmune ailments in young women, removing a potential overhang of legal uncertainty for the company.Concurrently, Merck received a regulatory boost in China, where health authorities proposed granting priority review status to its doravirine/islatravir tablet, a two-drug regimen for adult HIV-1 infection. This designation could accelerate the drug's path to market in a key region. Furthermore, analyst sentiment remained positive, with Goldman Sachs reaffirming its Buy rating on Merck and maintaining a $137 price target, providing additional confidence to investors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187394428","isCrawlerRequest":true}